Bayes Pharma.ai connects evidence, models, assumptions, uncertainty, reviewers, and rationale across innovator, generic, clinical, and governed biomedical research workflows.
The parent homepage routes you to the right product. Detailed modules, methods, and workspaces live inside each focused product experience.
What should the program do next?
Connect discovery, translation, developability, clinical MIDD, regulatory evidence, and lifecycle learning around the next accountable development decision.
What evidence moves this product toward a reviewable ANDA?
Connect reference-product intelligence, product and analytical design, scale-up, bioequivalence, quality, and ANDA execution in one controlled program record.
What does this patient review need next?
Support diagnostic context, medication-safety review, patient-specific Bayesian dosing, and TDM follow-up with clinician-reviewable rationale.
What does the evidence actually support?
Connect research planning, model intelligence, scientific compute, biological assets, and evidence governance inside one authoritative project record.
The products stay specialized. What they share is a deliberate way to frame a question, inspect evidence and uncertainty, record qualified review, and carry rationale into the next action.
State the question, options, intended use, owner, and consequence of being wrong.
Keep sources, methods, models, versions, assumptions, and context attached.
Show limitations, conflicts, missing evidence, applicability, and open conditions.
Name reviewers, authority, rationale, dissent, conditions, and approval boundaries.
Move the decision, owner, follow-up, and learning into the next milestone or review.
Innovator, Generics, Clinical, and BioAtlas retain the methods, language, evidence standards, and governance appropriate to their own decision context.
The public tour below uses explicitly illustrative content to show the same review fields across three different product contexts. It contains no live patient, program, or customer data.
The decision record shows what is being decided, which evidence is current, what remains uncertain, and who must review the next step.
Bayes Pharma.ai products organize evidence, analysis, and review. They do not autonomously approve a development program, qualify a model or deployment, file with a regulator, diagnose, or prescribe.
Sources, versions, methods, applicability, and changes remain inspectable.
Limitations, conflicts, missing evidence, and open conditions are not hidden.
Qualified reviewers, approval boundaries, conditions, and dissent stay visible.
What was considered, decided, assigned, and learned remains connected over time.
Responsible-use boundary: intended use, source quality, validation, model qualification, local procedures, security, documentation, and qualified human review remain required for every development, regulatory, and clinical use.
Read responsible-use principlesWhich consequential decision is difficult today? Start with one question, not a broad platform rollout.
Where is the scientific context fragmenting? Identify the evidence, assumptions, review, or ownership that gets lost.
Who must review and authorize the outcome? Define the qualified authority and a credible first result.
Tell us which product fits, where the evidence or ownership is fragmented, and what a credible first outcome would look like. We will shape the conversation around one reviewable decision path.
Do not include confidential program details or identifiable patient information in this public request form.
Free public chat · No API key · Product claims use the public catalog · Do not share confidential or identifiable patient data.